StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Research analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the stock.

Bio-Path Trading Up 4.5 %

Shares of NASDAQ:BPTH opened at $0.82 on Wednesday. Bio-Path has a 52-week low of $0.59 and a 52-week high of $9.99. The business’s 50 day simple moving average is $0.89 and its two-hundred day simple moving average is $1.07.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.